(Neo:ABXX.NE),(OTC US:ABXXF),(Other OTC:ABXXF), TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company“), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing“), and producer of the SmarterMarkets(TM) Podcast, today announced the […]

(PinkSheets:BCDS),(Pinksheets:BCDS), ROBESONIA, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) — Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and decentralized finance company, today announced it has entered into a Blockchain & Development Partnership Agreement with Super Studios USA, an emerging powerhouse in film, television, and mixed-use real estate development. Under the terms of the agreement, Super

(NASDAQ:ZVRA), CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after

(TASE:BWAY.TA),(NasdaqGM:BWAY), Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders,

(TSX:TSAT),(NASDAQ:TSAT), OTTAWA, Oct. 27, 2025 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world's largest and most innovative satellite operators, has scheduled a conference call on Tuesday, November 4, 2025, at 10:30 a.m. EST to discuss its financial results for the three and nine month periods ended September 30, 2025. Prior to

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Conference call today at 8:30 a.m. ET GlobeNewswire October 27, 2025 CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market GlobeNewswire October 27, 2025 MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced

MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101 Korea's First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in Patients with Acute Pneumonia GlobeNewswire October 27, 2025 SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) — MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing

Blaqclouds Executes Blockchain Partnership with Super Studios USA, Led by Former Ridley Scott & Associates Executive Producer Developing a Billion-Dollar Entertainment Complex in Texas GlobeNewswire October 27, 2025 ROBESONIA, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) — Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and decentralized finance company, today announced it has entered into a

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call – Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 GlobeNewswire October 27, 2025 CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people